{"id":69531,"date":"2026-07-07T20:55:58","date_gmt":"2026-07-07T12:55:58","guid":{"rendered":"https:\/\/flcube.com\/?p=69531"},"modified":"2026-07-07T20:56:00","modified_gmt":"2026-07-07T12:56:00","slug":"hainan-shuangcheng-pharmaceutical-secures-10m-us-licensing-deal-for-sc-c141-rd-project","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69531","title":{"rendered":"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hainan Shuangcheng Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002693:SHE\">SHE: 002693<\/a>) announced an <strong>exclusive licensing agreement<\/strong> with undisclosed <strong>American Company A<\/strong>, granting exclusive <strong>commercialization rights<\/strong> for the <strong>SC-C141 project<\/strong> in the <strong>United States<\/strong>, with potential license fees totaling <strong>USD 10 million<\/strong> upon milestone achievement.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-commercial-framework\" class=\"wp-block-heading\">Deal Structure &amp; Commercial Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Hainan Shuangcheng Pharmaceutical (SHE: 002693) and American Company A (undisclosed)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>SC-C141 project (early-stage research and development)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>United States<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive commercialization rights<\/td><\/tr><tr><td><strong>Commercial Responsibility<\/strong><\/td><td>Company A responsible for all US commercial-related activities<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Up to USD 10 million in milestone-based license fees + profit sharing on US sales post-launch<\/td><\/tr><tr><td><strong>Current Stage<\/strong><\/td><td>Research and development phase<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-risk-disclosure-amp-development-context\" class=\"wp-block-heading\">Risk Disclosure &amp; Development Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development Stage:<\/strong> SC-C141 currently in <strong>early research and development<\/strong><\/li>\n\n\n\n<li><strong>Inherent Risks:<\/strong> Drug R&amp;D characterized by <strong>long development cycles<\/strong>, <strong>high capital investment<\/strong>, and <strong>significant technical risk<\/strong><\/li>\n\n\n\n<li><strong>Uncertainty Factors:<\/strong> Project progress and R&amp;D outcomes may not meet expectations due to scientific, regulatory, or competitive challenges<\/li>\n\n\n\n<li><strong>Timeline:<\/strong> No specific clinical development timeline disclosed; typical preclinical-to-approval pathway spans 8-12 years<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-partnership-benefits\" class=\"wp-block-heading\">Strategic Rationale &amp; Partnership Benefits<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Strategic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Hainan Shuangcheng<\/strong><\/td><td>Secures upfront validation and potential funding for early-stage asset; leverages US partner&#8217;s development expertise and commercial infrastructure; diversifies international partnership portfolio<\/td><\/tr><tr><td><strong>American Company A<\/strong><\/td><td>Gains access to novel Chinese-developed therapeutic candidate at attractive early-stage valuation; expands pipeline with potential first-in-class or best-in-class opportunity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Hainan Shuangcheng Pharmaceutical, a publicly traded Chinese pharmaceutical company, has historically focused on generic formulations and established drug products, making this early-stage R&amp;D partnership a strategic expansion into innovative drug development.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-considerations\" class=\"wp-block-heading\">Market Context &amp; Competitive Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chinese Pharma Innovation:<\/strong> Part of broader trend of Chinese pharmaceutical companies developing novel compounds and seeking international partnerships for global development<\/li>\n\n\n\n<li><strong>US Market Access:<\/strong> Partnership provides pathway to world&#8217;s largest pharmaceutical market with premium pricing potential<\/li>\n\n\n\n<li><strong>Early-Stage Valuation:<\/strong> USD 10 million total milestone value suggests relatively modest upfront commitment, typical for preclinical assets with unproven mechanisms<\/li>\n\n\n\n<li><strong>Confidentiality:<\/strong> Partner identity undisclosed, potentially indicating either competitive sensitivity or early-stage exploratory collaboration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-implications-amp-investor-considerations\" class=\"wp-block-heading\">Financial Implications &amp; Investor Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Recognition:<\/strong> Milestone payments contingent on successful R&amp;D achievements; no guaranteed revenue stream<\/li>\n\n\n\n<li><strong>Profit Sharing Structure:<\/strong> Post-launch profit participation provides long-term upside but dependent on successful commercialization<\/li>\n\n\n\n<li><strong>Capital Allocation:<\/strong> Agreement may reduce Hainan Shuangcheng&#8217;s internal R&amp;D funding requirements for SC-C141 project<\/li>\n\n\n\n<li><strong>Risk Management:<\/strong> Partnership transfers significant development and commercial risk to US partner while retaining profit participation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the Hainan Shuangcheng licensing agreement, including milestone payments, development timelines, and commercial prospects. Actual results may differ materially due to risks inherent in pharmaceutical R&amp;D, including scientific feasibility, regulatory approvals, competitive developments, and market dynamics. The SC-C141 project remains in early development with no guarantee of clinical or commercial success.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u53cc\u6210\u836f\u4e1a\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u516c\u53f8\u7b7e\u8ba2\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u53cc\u6210\u836f\u4e1a\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u516c\u53f8\u7b7e\u8ba2\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-ceb57792-f215-420a-86d4-cc4db0d74631\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u53cc\u6210\u836f\u4e1a\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u516c\u53f8\u7b7e\u8ba2\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\">\u53cc\u6210\u836f\u4e1a\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u516c\u53f8\u7b7e\u8ba2\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u53cc\u6210\u836f\u4e1a\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u516c\u53f8\u7b7e\u8ba2\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ceb57792-f215-420a-86d4-cc4db0d74631\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[3321,3320],"class_list":["post-69531","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-she-002693","tag-shuangcheng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American Company A, granting exclusive commercialization rights for the SC-C141 project in the United States, with potential license fees totaling USD 10 million upon milestone achievement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69531\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project\" \/>\n<meta property=\"og:description\" content=\"Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American Company A, granting exclusive commercialization rights for the SC-C141 project in the United States, with potential license fees totaling USD 10 million upon milestone achievement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69531\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T12:55:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T12:56:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69531#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69531\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project\",\"datePublished\":\"2026-07-07T12:55:58+00:00\",\"dateModified\":\"2026-07-07T12:56:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69531\"},\"wordCount\":475,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"SHE: 002693\",\"Shuangcheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69531#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69531\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69531\",\"name\":\"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-07T12:55:58+00:00\",\"dateModified\":\"2026-07-07T12:56:00+00:00\",\"description\":\"Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American Company A, granting exclusive commercialization rights for the SC-C141 project in the United States, with potential license fees totaling USD 10 million upon milestone achievement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69531#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69531\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69531#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project - Insight, China&#039;s Pharmaceutical Industry","description":"Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American Company A, granting exclusive commercialization rights for the SC-C141 project in the United States, with potential license fees totaling USD 10 million upon milestone achievement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69531","og_locale":"en_US","og_type":"article","og_title":"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project","og_description":"Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American Company A, granting exclusive commercialization rights for the SC-C141 project in the United States, with potential license fees totaling USD 10 million upon milestone achievement.","og_url":"https:\/\/flcube.com\/?p=69531","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T12:55:58+00:00","article_modified_time":"2026-07-07T12:56:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69531#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69531"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project","datePublished":"2026-07-07T12:55:58+00:00","dateModified":"2026-07-07T12:56:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69531"},"wordCount":475,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["SHE: 002693","Shuangcheng Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69531#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69531","url":"https:\/\/flcube.com\/?p=69531","name":"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-07T12:55:58+00:00","dateModified":"2026-07-07T12:56:00+00:00","description":"Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American Company A, granting exclusive commercialization rights for the SC-C141 project in the United States, with potential license fees totaling USD 10 million upon milestone achievement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69531#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69531"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69531#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&amp;D Project"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69531"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69531\/revisions"}],"predecessor-version":[{"id":69533,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69531\/revisions\/69533"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}